Markets:

Overview

News

Currencies

International

Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

70.12 -0.10 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 20, 2023

Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.

Via Benzinga

Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High

July 20, 2023

Via Investor Brand Network

Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday ↗

July 20, 2023

U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose...

Via Benzinga

Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease ↗

December 15, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗

July 18, 2023

Via Benzinga

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

June 12, 2023

Webcast scheduled for Thursday, June 15 at 8:30am PT

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Present at the Jefferies Global Healthcare Conference

June 05, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗

May 18, 2023

Via Benzinga

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

May 09, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

May 08, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

May 03, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

April 24, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay ↗

April 18, 2023

Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).

Via Benzinga

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗

March 28, 2023

Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...

Via Benzinga

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

March 13, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

March 02, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

Tarsus Added to NASDAQ Biotechnology Index

December 16, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

December 15, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

November 09, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

October 25, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Announces Transition Plans for Board of Directors

October 11, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

October 06, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

September 29, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 ↗

August 01, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 03, 2022

Tuesday's session saw 211 companies set new 52-week lows.

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

31 Stocks Moving In Monday's Mid-Day Session ↗

May 02, 2022

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...

Via Benzinga

66 Biggest Movers From Yesterday ↗

May 03, 2022

Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today